ImaginAb advances two solid Tumor Radiopharmaceutical Therapy (RPT) candidates towards clinical development May 18, 2023 Categories: Health Care Tags: ImaginAb
ImaginAb and Quibim partner to revolutionize immune status diagnosis and immunotherapy prediction May 2, 2023 Categories: Health Care Tags: ImaginAb
ImaginAb launching clinical trial for renal cancer and malignant melanoma December 12, 2022 Categories: Health Care Tags: ImaginAb
ImaginAb executes license and supply agreement for CD8 ImmunoPET Technology November 15, 2022 Categories: Health Care Tags: ImaginAb
Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies November 11, 2022 Categories: Health Care Tags: ImaginAb
ImaginAb announces first patient dosed in Australia in Phase IIb iPREDICT trial October 26, 2022 Categories: Health Care Tags: ImaginAb
ImaginAb and Cyclotek enter into manufacturing and distribution agreement for CD8 ImmunoPET Agent in Australia October 17, 2022 Categories: Health Care Tags: ImaginAb
ImaginAb announces new supply agreement to supply Genmab A/S with its investigational CD8 ImmunoPET agent May 11, 2022 Categories: Health Care Tags: ImaginAb
ImaginAb Inc. and DongCheng Pharmaceutical Group announce plans for a CD8 ImmunoPET commercial partnership January 26, 2022 Categories: Health Care Tags: ImaginAb
ImaginAb announces extension of long-standing partnership with Boehringer Ingelheim July 23, 2021 Categories: Health Care Tags: ImaginAb
ImaginAb aims to help our immune systems better detect late-stage cancer June 10, 2021 Categories: Health Care Tags: ImaginAb
ImaginAb completes $12.8 million financing to accelerate growth plans June 4, 2021 Categories: Health Care Tags: ImaginAb
ImaginAb News: ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology January 28, 2021 Categories: Uncategorized Tags: ImaginAb
ImaginAb News: Announces license and supply agreement with Pfizer for CD8 immunoPET technology January 7, 2021 Categories: Uncategorized Tags: ImaginAb
